<DOC>
	<DOCNO>NCT00861783</DOCNO>
	<brief_summary>Studies do laboratory demonstrate beneficial effect ON 01910.Na , new , unapproved drug , use combination either irinotecan oxaliplatin , two approve , extensively use anti-cancer drug . In laboratory study , mice implant cell ( Bel-7402 cell ) come human tumor use model liver cancer . In mouse treat , Bel-7402 cell form large tumor . In mouse treat ON 01910.Na , irinotecan oxaliplatin alone , growth tumor reduce compare untreated group . When combination ON 01910.Na irinotecan ON 01910.Na oxaliplatin use treat mouse , tumor growth completely inhibit . Another observation study toxicity increase combination use . These result similar result study support hypothesis combination ON 01910.Na irinotecan ON 01910.Na oxaliplatin would effective tolerable treatment liver type cancer . The primary objective phase 1 study find dos ON 01910.Na combination either irinotecan oxaliplatin safe tolerable patient liver type cancer .</brief_summary>
	<brief_title>Safety ON 01910.Na Irinotecan ON 01910.Na Oxaliplatin Patients With Hepatoma</brief_title>
	<detailed_description>This open-label , 2-arm , dose-escalation combination-therapy study patient hepatoma advanced malignancy assign Investigator dose either irinotecan plus ON 01910.Na ( Group A ) , oxaliplatin plus ON 01910.Na ( Group B ) . Note : As Amendment 2 protocol , treatment irinotecan arm study ( Group A ) close enrollment patient enrol Group B , oxaliplatin treatment arm . Patients enrol 1 4 Cohorts ( 4 sequential Cohorts Group B ) 3 patient . Up 6 additional patient test MTD .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>Male female patient ≥18 year age histologically cytologically confirm hepatoma solid tumor metastatic progressive , standard therapy hold curative potential irinotecan oxaliplatin reasonable treatment option . Patients must evaluable disease , either measurable imaging informative tumor marker ( ) . Eastern Collaborative Oncology Group ( ECOG ) Performance Status ≤2 . Life expectancy &gt; 12 week . Any acute chronic adverse effect prior chemotherapy resolve &lt; Grade 2 determine CTCAE v3 criterion . Existing planned central venous access 2channel infusion catheter system . Laboratory value meet following criterion : Absolute neutrophil count ≥1,500 cells/µL ; Platelets ≥100,000 cells/µL ; Total bilirubin ≤1.5 time upper limit normal ; AST ( SGOT ) ≤2.5 time upper limit normal ; ALT ( SGPT ) ≤2.5 time upper limit normal ; Serum creatinine ≤1.5 mg/dL measure creatinine clearance ≥50 mL/min ; Negative βhCG test woman childbearing potential ( defined woman ≤50 year age history amenorrhea ≤12 month prior study entry ) . Patients primary liver cancer hepatic metastasis eligible enroll , provide meet follow : Total bilirubin ≤2 mg/dL ; AST ALT ≤5 time institutional upper limit normal ; Ascites , present , manageable diuretic agent alone . If history treat brain metastasis , must clinically stable ≥4 week prior enrollment . Women pregnant lactating . Patients chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study . Severe liver dysfunction ( ChildPugh Class C uncompensated Class B persistent encephalopathy , persistent ascites , prothrombin time &gt; 1.5 time upper limit normal ) present . Patients history esophageal bleeding exclude unless arices sclerosed band bleed episode occur prior 6 month . Contraindications , include know hypersensitivity , assign chemotherapy agent ( i.e. , irinotecan oxaliplatin ) . Prior receipt ON 01910.Na prior participation protocol . Use investigational agent within 4 week study enrollment . Uncontrolled intercurrent illness include , limited ongoing active infection psychiatric illness/social situation would limit compliance study requirement , determine Investigator . Patients ascites require active medical management include paracentesis , peripheral bilateral edema hyponatremia ( define serum sodium value &lt; 134 Meq/L ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>oxaliplatin</keyword>
	<keyword>diaminocyclohexane oxalatoplatinum</keyword>
	<keyword>oxalatoplatin</keyword>
	<keyword>oxalatoplatinum</keyword>
	<keyword>Eloxatin</keyword>
</DOC>